product name Azelnidipine
Description: Azelnidipine (also called UR-12592), a novel dihydropyridine derivative, is a L-type calcium channel blocker, and an antihypertensive drug. Acute administration of azelnidipine prevents a sudden drop of cardiac function after acute stress. Unlike other L-type calcium channel blockers, azelnidipine causes minimal stimulation of the sympathetic nervous system despite its significant depressor effect. Azelnidipine may have a protective role in inflammation in atherosclerosis.
References: Hypertens Res. 2003 Mar;26(3):201-8; Int J Pharm. 2008 Mar 3;351(1-2):55-60.
582.65
Formula
C33H34N4O6
CAS No.
123524-52-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 117 mg/mL (200.8 mM)
Water: <1 mg/mL
Ethanol: 7 mg/mL (12.01 mM)
Solubility (In vivo)
Synonyms
UR-12592
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19403522
| In Vitro |
In vitro activity: Azelnidipine is a newly developed long-acting calcium channel blocker with unique pharmacological features, e.g. cardiac slowing action and high affinity to vascular tissues, which distinguishes itself from other calcium channel blockers. Azelnidipine, thus, became a new generation of calcium channel blocker that can be used for the treatment of hypertensive patients with or without potential ischemic heart diseases. Because this new calcium antagonist is highly lipid soluble, it is retained in the vascular wall after clearance from the blood and continues to elicit a hypotensive effect. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Hypertens Res. 2003 Mar;26(3):201-8; Int J Pharm. 2008 Mar 3;351(1-2):55-60. |
Related Posts
product name Azelnidipine
Description: Azelnidipine (also called UR-12592), a novel dihydropyridine derivative, is a L-type calcium channel blocker, and an antihypertensive drug. Acute administration of azelnidipine prevents a sudden drop of cardiac function after acute stress. Unlike other L-type calcium channel blockers, azelnidipine causes minimal stimulation of the sympathetic nervous system despite its significant depressor effect. Azelnidipine may have a protective role in inflammation in atherosclerosis.
References: Hypertens Res. 2003 Mar;26(3):201-8; Int J Pharm. 2008 Mar 3;351(1-2):55-60.
582.65
Formula
C33H34N4O6
CAS No.
123524-52-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 117 mg/mL (200.8 mM)
Water: <1 mg/mL
Ethanol: 7 mg/mL (12.01 mM)
Solubility (In vivo)
Synonyms
UR-12592
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19403522
| In Vitro |
In vitro activity: Azelnidipine is a newly developed long-acting calcium channel blocker with unique pharmacological features, e.g. cardiac slowing action and high affinity to vascular tissues, which distinguishes itself from other calcium channel blockers. Azelnidipine, thus, became a new generation of calcium channel blocker that can be used for the treatment of hypertensive patients with or without potential ischemic heart diseases. Because this new calcium antagonist is highly lipid soluble, it is retained in the vascular wall after clearance from the blood and continues to elicit a hypotensive effect. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Hypertens Res. 2003 Mar;26(3):201-8; Int J Pharm. 2008 Mar 3;351(1-2):55-60. |